News | July 18, 2022
Glaucoma Research Foundation launches catalyst for a to prevent and cure neurodegeneration
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
The new facility at Dombivli is the fifth ASG Eye Hospital in Maharashtra
Researchers have found out that myopia often leads to an abnormal increase in axial length. When the axial length grows to more than 25mm, especially with age, problems like cataracts or glaucoma can appear
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
Subscribe To Our Newsletter & Stay Updated
